References
- Anscher MS, Kong F-M, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998; 41: 1029–35
- Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TGF-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 988–95
- Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol 2002; (Suppl1): 26–33
- Kong F-M, Anscher MS, Murase T, Abbott BD, Iglehart D, Jirtle RL. Elevated transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995; 222: 155–62
- Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999; 86: 1712–9
- Martin M, Lefaix J, Delanian S. TGFβ1 and radiation fibrosis: A master switch and a specific therapeutic target?. Int J Radiat Oncol Biol Phys 2000; 47: 277–90
- Grainger DJ, Mosedale DE, Metcalfe JC. TGFβ in blood: A complex problem. Cytokine & Growth Factor Reviews 2000; 11: 133–45